Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of primary peritoneal carcinoma

Authors

  • Armando Sardi The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD http://orcid.org/0000-0003-4132-9489
  • Arkadii Sipok The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD
  • Teresa P. Díaz-Montes The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD
  • Michelle Sittig The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD http://orcid.org/0000-0003-2641-1564
  • Carol Nieroda The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD
  • Kimberley Studeman The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD
  • Vadim Gushchin The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD

DOI:

https://doi.org/10.4081/joper.2017.57

Keywords:

Primary peritoneal carcinoma, cytoreductive surgery, HIPEC, outcomes

Abstract

Primary peritoneal carcinoma (PPC) is rare tumor, traditionally treated with surgical debulking and systemic chemotherapy (SC) with 30% five-year survival rate. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) may improve long-term survival. Thirty patients with PPC were identified. Twenty-three patients underwent CRS/HIPEC as initial treatment (group I) and 7 for recurrent disease (group II). Peritoneal cancer index (PCI), cytoreduction scores (CC), overall survival (OS) and progressionfree survival (PFS) were estimated using Kaplan-Meier survival analysis. FIGO stages II/III/IV at diagnosis were 2/20/7 (1 was not classified). Median time from diagnosis to CRS/HIPEC was 2 months and 8 months in groups I and II, respectively. PCI≥20 was seen in 16 (70%) and 4 (57%) in groups I and II, respectively. Complete cytoreduction (CC 0-1) was achieved in 30/32 (94%) CRS/HIPEC procedures. Median follow-up was 39 months (range: 11-250). PFS at 1, 3, 5-years was 80%, 75%, 59%, respectively. OS 1, 3, 5- years from CRS/HIPEC was 90%, 68%, 55%. CRS/HIPEC and adjuvant SC provides five-year survival rate higher than previously reported for PPC patients who received conventional therapy with surgical debulking and SC.

Downloads

Download data is not yet available.

Author Biographies

Armando Sardi, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD

Director, The Institute for Cancer Care at Mercy

Chief, Surgical Oncology

Arkadii Sipok, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD

Research Fellow

Surgical Oncology

Teresa P. Díaz-Montes, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD

Gynecologic Oncologist

Associate Director, Segal Ovarian Cancer Institute

Michelle Sittig, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD

RN

Surgical Oncology

Carol Nieroda, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD

Surgical Onocology

Vadim Gushchin, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD

Surgical Oncologist

Director, GI Oncology

 

Downloads

Published

2017-08-02

How to Cite

1.
Sardi A, Sipok A, Díaz-Montes TP, Sittig M, Nieroda C, Studeman K, Gushchin V. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of primary peritoneal carcinoma. J Peritoneum [Internet]. 2017 Aug. 2 [cited 2024 Dec. 22];2(2). Available from: https://joper.pagepress.net/index.php/joper/article/view/57

Issue

Vol 2, No 2 (2017)

Section

Original Articles

License

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

An Open Access Publication is one that meets the following two conditions:

  1. the author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.
  2. a complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.